AbbVie (ABBV)
(Delayed Data from NYSE)
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
by Zacks Equity Research
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $107.72, marking a +0.61% move from the previous day.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval
by Zacks Equity Research
Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.
AbbVie (ABBV) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $106.40, moving -1.23% from the previous trading session.
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
by Kinjel Shah
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $106.48, moving -0.93% from the previous trading session.
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
by Zacks Equity Research
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
by Zacks Equity Research
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
by Kinjel Shah
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Zacks Value Investor Highlights: AbbVie, Chevron, RH, Aon and Kroger
by Zacks Equity Research
Zacks Value Investor Highlights: AbbVie, Chevron, RH, Aon and Kroger
Is Berkshire Hathaway Trading in its Stock Portfolio?
by Tracey Ryniec
If Buffett believes in holding stocks forever, why is Berkshire selling in less than a year?
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $110.36 in the latest trading session, marking a +1.22% move from the prior day.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
Top Analyst Reports for Facebook, AbbVie & 3M
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), AbbVie Inc. (ABBV), and 3M Company (MMM).
Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment
by Zacks Equity Research
The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.